Evan S. Dellon, MD, MPH, Gastroenterologist and Professor of Medicine and Adjunct Professor of Epidemiology at the University of North Carolina Chapel Hill, discusses treatment strategies for eosinophilic esophagitis (EoE) and describes the mechanism of action of the investigational drug ‘1104.
EoE is a chronic, allergic inflammatory disease due to the buildup of eosinophils in the lining of the esophagus. Signs and symptoms vary but EoE patients often experience difficulty feeding, poor weight gain, heartburn, regurgitation, and dysphagia.
As Dr. Dellon explains, there is currently no FDA-approved treatment specifically for EoE. As such, EoE is usually managed by figuring out if there is a food trigger through elimination diets and avoiding any food that causes a reaction in the esophagus. Additionally, steroids may be used – it is particularly common for physicians to adapt asthma medications such as budesonide or fluticasone.
Fortunately, Revolo has recently received approval to begin a phase 2 trial of the drug, ‘1104, for the treatment of EoE. ‘1104 is an oral medication that is derived from a bacterium, Mycobacterium tuberculosis, which is involved in resetting the immune system.
For more information about the phase 2 study of ‘1104, visit here.
To learn more about EoE and other rare gastrointestinal disorders, visit checkrare.com/diseases/gastrointestinal-diseases/
